Tilray, a Canadian medical cannabis producer, has successfully exported its medical cannabis products to New Zealand.

The products will be distributed to pharmacies that serve registered patients in New Zealand.

Tilray President Brendan Kennedy said he is proud to offer patients in New Zealand access to quality-controlled, pharmaceutical-grade medical cannabis product.

“With Tilray products available in six countries representing four continents, we further our global mission of serving patients in need in a timeframe that matters,” Kennedy said.

A leading New Zealand pharmaceutical distributor has signed an agreement with Tilray to supply pharmacies across the country with medical cannabis products, such as formulated medical cannabis oils containing tetrahydrocannabinol (THC) and cannabidiol (CBD).

Since 2016, Tilray has exported products to North America, South America, Europe, and Australia and supplied medical cannabis products to authorized patients. In Australia, Tilray has partnered up with the University of Sydney and the government of New South Wales to develop a novel treatment for chemotherapy-induced nausea and vomiting.

Earlier this year, Tilray received GMP certification, making the firm the first licensed medical cannabis producer in Canada to do so. GMP is an internationally recognized standard that ensures quality and purity control in the production process.